Guttman‐Yassky, E.

Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*

Wollenberg, A., Blauvelt, A., Guttman‐Yassky, E., Worm, M., Lynde, C., Lacour, J. ‐., Spelman, L., Katoh, N., Saeki, H., Poulin, Y., et al. (2021) · British Journal of Dermatology

Dermatology and Skin DiseasesAsthma and respiratory diseases

Cited by 638

Conjunctivitis in dupilumab clinical trials

Akinlade, B., Guttman‐Yassky, E., Bruin‐Weller, M., Simpson, E. L., Blauvelt, A., Cork, M. J., Prens, E., Asbell, P., Akpek, E., Corren, J., et al. (2019) · British Journal of Dermatology

Dermatology and Skin DiseasesOcular Surface and Contact Lens

Cited by 442

Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials

Simpson, E. L., Lacour, J. ‐., Spelman, L., Galimberti, R., Eichenfield, L. F., Bissonnette, R., King, B. A., Thyssen, J. P., Silverberg, J. I., Bieber, T., et al. (2020) · British Journal of Dermatology

Dermatology and Skin DiseasesPsoriasis: Treatment and Pathogenesis

Cited by 396

Whole genome sequencing identifies novel genetic mutations in patients with eczema herpeticum

Bin, L., Malley, C., Taylor, P., Preethi Boorgula, M., Chavan, S., Daya, M., Mathias, M., Shankar, G., Rafaels, N., Vergara, C., et al. (2021) · Allergy

Dermatology and Skin DiseasesHerpesvirus Infections and Treatments

Cited by 33

CLA+ memory T cells in atopic dermatitis: CLA+ T cells and atopic dermatitis

Nicolàs, L. S. S., Czarnowicki, T., Akdis, M., Pujol, R. M., Lozano‐Ojalvo, D., Leung, D. Y. M., Guttman‐Yassky, E., & Santamaria‐Babí, L. F. (2024) · Allergy

Dermatology and Skin DiseasesPsoriasis: Treatment and Pathogenesis

Cited by 25